Bio Essence Corporation entered into a definitive Asset Purchase Agreement on April 20, 2026 to acquire the MediFlow AI platform from Zhituo Software Co., Limited. The acquisition, announced on April 27, 2026, is valued at $3.5 million and will be paid in restricted common stock of Bio Essence.
The deal expands Bio Essence’s capabilities in the AI‑in‑fitness and wellness market, which was valued at $10.68 billion in 2025 and is projected to reach $57.80 billion by 2035. By owning the MediFlow platform—complete with source code, system architecture, databases, and proprietary algorithms—the company can deliver integrated AI‑driven health and wellness solutions to its existing OEM client base and accelerate product development.
Financially, the purchase price is significant relative to Bio Essence’s market capitalization of $4.18 million as of April 24, 2026, underscoring management’s confidence in the platform’s potential to drive future growth and justify a transformative investment.
The company plans to integrate MediFlow into its product portfolio, leveraging its OEM relationships to introduce new revenue streams and strengthen competitive differentiation in a rapidly expanding market. The acquisition aligns with Bio Essence’s broader strategy to focus on AI and digital wellness, positioning it for long‑term growth in a high‑growth sector.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.